Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Celldex Therapeutics Stock Is Soaring Today

By Cory Renauer – Jun 19, 2020 at 4:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market is reacting to large stock purchases from inside and outside the company.

What happened

Shares of Celldex Therapeutics (CLDX -2.78%), a clinical-stage biotechnology company, are rising in response to insider stock purchases and large equity stakes acquired by independent investment firms. A stock market encouraged by the signs of confidence has driven shares 29.2% higher as of 3:42 p.m. EDT on Friday.

So what 

Shares of Celldex rose earlier this week following the presentation of results from a trial with CDX-0159 and 32 healthy patients. A single dose of CDX-1059 suppressed production of plasma tryptase, which could be a big deal for people who frequently break out in hives.

Person drawing an upward sloping chart on a giant chalkboard.

Image source: Getty Images.

Itchy hives that occur for more than six weeks at a time, a condition called chronic urticaria, affect an estimated 1 million to 3 million Americans, and many of them can't control their breakouts with available treatments. If CDX-0159 becomes a successful new treatment for this and other indications, it could generate 10-figure annual sales at its peak.

It's way too early to assume CDX-1059 will succeed as a treatment for anything, but that hasn't stopped RTW Investments and Ikarian Capital from acquiring a combined 17% of Celldex's outstanding shares. In addition to two firms investing heavily, Celldex also disclosed direct purchases of stock by more than a dozen insiders, including the CEO, that occurred on Thursday.

Now what

Despite its recent run-up, Celldex sports a relatively low $470 million market cap that could swell to several times its size if the company can report positive results from studies with actual patients. The company plans to begin a phase 1 study with patients who suffer from chronic urticaria by the end of the year.

While it's too early to assume Celldex has a potential new treatment for millions of people with chronic hives, it's hard to ignore the signs of confidence exhibited by those on the inside. Before following along, it's important to know this company made its stock market debut over a decade ago but still hasn't reported any late-stage clinical trial successes.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
$27.98 (-2.78%) $0.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.